ADC Therapeutics Q3 net income beats analyst expectations

Reuters

2025/11/10

ADC <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 net income beats analyst expectations

Overview

ADC Therapeutics Q3 net income and income from operations beat analyst expectations
Net product revenues for Q3 2025 declined due to lower sales volume
Completed $60 mln PIPE financing to expand ZYNLONTA and strengthen balance sheet

Outlook

ADC Therapeutics expects LOTIS-7 data by end of 2025
Company anticipates LOTIS-5 topline results in 1H 2026
Recent financing extends cash runway into 2028

Result Drivers

PIPE FINANCING - Completed $60 mln PIPE financing to support ZYNLONTA expansion and strengthen balance sheet
REVENUE DECLINE - Lower sales volume led to a decline in Q3 net product revenues despite higher prices

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income	Beat	-$40.97 mln	-$43 mln (5 Analysts)
Q3 Income from Operations	Beat	-$30.97 mln	-$34.60 mln (5 Analysts)
Q3 Basic EPS		-$0.30
Q3 Operating Expenses		-$47.40 mln

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for ADC Therapeutics SA is $7.50, about 46.1% above its November 7 closing price of $4.04

Press Release: ID:nPn8rfSYRa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582485876"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582485876\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582485876?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582485876","market":"us","top_or_hot":-1,"title":"ADC Therapeutics Q3 net income beats analyst expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net income beats analyst expectations</title></head><body><p><span>Overview</span></p><ul><li><p>ADC Therapeutics Q3 net income and income from operations beat analyst expectations</p></li><li><p>Net product revenues for Q3 2025 declined due to lower sales volume</p></li><li><p>Completed $60 mln PIPE financing to expand ZYNLONTA and strengthen balance sheet</p></li></ul><p><span>Outlook</span></p><ul><li><p>ADC Therapeutics expects LOTIS-7 data by end of 2025</p></li><li><p>Company anticipates LOTIS-5 topline results in 1H 2026</p></li><li><p>Recent financing extends cash runway into 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PIPE FINANCING - Completed $60 mln PIPE financing to support ZYNLONTA expansion and strengthen balance sheet</p></li><li><p>REVENUE DECLINE - Lower sales volume led to a decline in Q3 net product revenues despite higher prices</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$40.97 mln</p></td><td><p>-$43 mln (5 Analysts)</p></td></tr><tr><td><p>Q3 Income from Operations</p></td><td><p>Beat</p></td><td><p>-$30.97 mln</p></td><td><p>-$34.60 mln (5 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.30</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>-$47.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/ADCT\">ADC Therapeutics SA</a> is $7.50, about 46.1% above its November 7 closing price of $4.04</p></li></ul><p>Press Release: <span>ID:nPn8rfSYRa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADC Therapeutics Q3 net income beats analyst expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADC Therapeutics Q3 net income beats analyst expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net income beats analyst expectations</title></head><body><p><span>Overview</span></p><ul><li><p>ADC Therapeutics Q3 net income and income from operations beat analyst expectations</p></li><li><p>Net product revenues for Q3 2025 declined due to lower sales volume</p></li><li><p>Completed $60 mln PIPE financing to expand ZYNLONTA and strengthen balance sheet</p></li></ul><p><span>Outlook</span></p><ul><li><p>ADC Therapeutics expects LOTIS-7 data by end of 2025</p></li><li><p>Company anticipates LOTIS-5 topline results in 1H 2026</p></li><li><p>Recent financing extends cash runway into 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PIPE FINANCING - Completed $60 mln PIPE financing to support ZYNLONTA expansion and strengthen balance sheet</p></li><li><p>REVENUE DECLINE - Lower sales volume led to a decline in Q3 net product revenues despite higher prices</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$40.97 mln</p></td><td><p>-$43 mln (5 Analysts)</p></td></tr><tr><td><p>Q3 Income from Operations</p></td><td><p>Beat</p></td><td><p>-$30.97 mln</p></td><td><p>-$34.60 mln (5 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.30</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>-$47.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/ADCT\">ADC Therapeutics SA</a> is $7.50, about 46.1% above its November 7 closing price of $4.04</p></li></ul><p>Press Release: <span>ID:nPn8rfSYRa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0FI:1","article_id":"2582485876","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582485876","pubTimestamp":1762778570,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ADC Therapeutics Q3 net income beats analyst expectationsOverviewADC Therapeutics Q3 net income and income from operations beat analyst expectationsNet product revenues for Q3 2025 declined due to low","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ADCT":"ADC Therapeutics SA","BK4505":"高瓴资本持仓"},"translate_title":"ADC Therapeutics第三季度净利润超出分析师预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADCT":0.9},"content_text":"ADC Therapeutics Q3 net income beats analyst expectationsOverviewADC Therapeutics Q3 net income and income from operations beat analyst expectationsNet product revenues for Q3 2025 declined due to lower sales volumeCompleted $60 mln PIPE financing to expand ZYNLONTA and strengthen balance sheetOutlookADC Therapeutics expects LOTIS-7 data by end of 2025Company anticipates LOTIS-5 topline results in 1H 2026Recent financing extends cash runway into 2028Result DriversPIPE FINANCING - Completed $60 mln PIPE financing to support ZYNLONTA expansion and strengthen balance sheetREVENUE DECLINE - Lower sales volume led to a decline in Q3 net product revenues despite higher pricesKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net IncomeBeat-$40.97 mln-$43 mln (5 Analysts)Q3 Income from OperationsBeat-$30.97 mln-$34.60 mln (5 Analysts)Q3 Basic EPS-$0.30Q3 Operating Expenses-$47.40 mlnAnalyst CoverageThe current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for ADC Therapeutics SA is $7.50, about 46.1% above its November 7 closing price of $4.04Press Release: ID:nPn8rfSYRaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}